Biglycan meets utrophin

Brown University researchers have found that systemic delivery of

biglycan, an extracellular matrix glycoprotein, decreases muscle pathology and improves muscle function in dystrophic mice.¹ The findings have been licensed to Tivorsan Pharmaceuticals Inc., which is working with the Brown team to optimize recombinant biglycan for delivery to patients with Duchenne muscular dystrophy...